KST-6051

· Kestrel Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KST-6051, covering 2026-04-15 to 2026-04-15. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation [Phase 1]

See pricing